showed a trendp = 0.12
Similarly, CST reduction showed a trend favoring the ranibizumab group (−61.3 μm [−128.7 to + 6.1] vs. + 29.4 μm [−18.2 to + 77.0], p = 0.12).
Similarly, CST reduction showed a trend favoring the ranibizumab group (−61.3 μm [−128.7 to + 6.1] vs. + 29.4 μm [−18.2 to + 77.0], p = 0.12).
However, our study diverges from some earlier findings in that changes in retinal thickness did not reach statistical significance, possibly due to the preoperative inability to accurately measure retinal thickness in patients with advanced cataracts [ 10 ].